Large-cap pharma with leading GLP-1/GIP franchise in diabetes and obesity.

Danish metabolic specialist; markets semaglutide and develops next-generation combinations.

Diversified pharma pursuing oral GLP-1 small molecules for obesity and diabetes.

Biotechnology company developing maritide (AMG 133), an antibody-peptide conjugate for obesity.

Swiss pharma/biotech that acquired Carmot Therapeutics to add oral and injectable incretin assets.

Family-owned pharma co-developing survodutide with Zealand Pharma for NASH and obesity.

Peptide-focused biotech; discovered and partnered GLP-1/glucagon dual agonist survodutide.

Structure-based drug design company developing oral small-molecule GLP-1R agonist GSBR-1290.